DNA methyltransferase 1 (DNMT1) is crucial for maintenance of methylation, gene regulation and chromatin stability 1-3 . DNA mismatch repair, cell cycle regulation in post-mitotic neurons 4,5 and neurogenesis 6 are influenced by DNA methylation. Here we show that mutations in DNMT1 cause both central and peripheral neurodegeneration in one form of hereditary sensory and autonomic neuropathy with dementia and hearing loss 7, 8 . Exome sequencing led to the identification of DNMT1 mutation c.1484A>G (p.Tyr495Cys) in two American kindreds and one Japanese kindred and a triple nucleotide change, c.1470-1472TCC>ATA (p.Asp490Glu-Pro491Tyr), in one European kindred. All mutations are within the targeting-sequence domain of DNMT1. These mutations cause premature degradation of mutant proteins, reduced methyltransferase activity and impaired heterochromatin binding during the G2 cell cycle phase leading to global hypomethylation and site-specific hypermethylation. Our study shows that DNMT1 mutations cause the aberrant methylation implicated in complex pathogenesis. The discovered DNMT1 mutations provide a new framework for the study of neurodegenerative diseases.
Neurodegenerative diseases are hallmarked by an increased rate of neuronal axonal loss. Neural development, neural survival and connectivity have been linked to DNA methylation and chromatin stability 1 . Here, we studied one form of neurodegeneration with both peripheral and central involvement: hereditary sensory and auto nomic neuropathy type 1 (HSAN1) with dementia and hearing loss. As a whole, HSAN1 has autosomal dominant inheritance with neuro degeneration that clinically manifests with loss of sensation leading to painless extremity injuries, infections and resultant amputations 9 . Serine palmitoyltransferase (encoded by SPTLC1 and SPTLC2) 10, 11 , atlastin1 (encoded by ATL1) 12 and Rasrelated GTPase 7 (encoded by RAB7) 13 have been linked to some HSAN1 kindreds, but the major ity of causative genes remain unknown. The specific form of HSAN1 investigated here has early onset dementia and sensorineural hear ing loss that tracks with sensory neuropathy 7, 8 . Pathologic studies of affected persons' nerve 7 , brain 14 and spinal cord ( Fig. 1) show axonal loss without interstitial infiltrative inclusions. Affected persons typically have early mortality and often require total care because of dementia, hearing loss and loss of ambulation from predominant sen sory ataxia. We investigated four kindreds ( Fig. 2a-d) , two of which were previously reported in detail 7, 8 . The affected persons in these kindreds had very similar phenotypes ( Table 1 ) and were healthy in their youth but developed worsening sensorineural deafness and sensory neuropathy by the age of 20-35 years. Progressive cogni tive and behavioral declines developed by their fourth decade. Brain imaging of the affected persons showed global atrophy and a reduced weight of the autopsied brains. Among the Japanese kindred, positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging suggested medial frontal and thalamic hypo metabolism 8 . Quantitative sensory testing, nerve conductions and nerve biopsy were indicative of lengthdependent progressive sensory axonal loss.
We performed a genomewide linkage analysis in kindred 1 and mapped to19p13.2 with a maximal log 10 odds (LOD) score of 6.38. Fine mapping analysis with haplotype construction narrowed the region to 3.4 Mb between D19S583 and D19S221. To increase the sequencing coverage and depth, we performed both Illumina GAII and Roche454 exome sequencing ( Supplementary Table 1 ). We filtered Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss 5 9 6 VOLUME 43 | NUMBER 6 | JUNE 2011 Nature GeNetics l e t t e r s all of the identified base alterations in the region against the dbSNP131 database. Bioinformatics analysis revealed a previously unidentified nonsynonymous heterozygous mutation in DNMT1 (c.1484A>G) resulting in Tyr495 changing to cysteine. Sequencing results con firmed that this alteration segregated with disease status. We subse quently sequenced all 41 exons of DNMT1 and found that kindred 3 (the American kindred) and kindred 4 (the Japanese kindred) have the same heterozygous mutation, c.1484A>G (p.Tyr495Cys), and kin dred 2 (the European kindred) contains three consecutive nucleotides with the heterozygous change c.1470-1472TCC>ATA (p.Asp490Glu-Pro491Tyr) ( Supplementary Fig. 1 ). All heterozygous mutations were absent in over 1,500 unaffected controls and were not reported in the Human Genome Mutation Database, the 1000 Genome browser or ten exomes sequenced as part of the Environmental Genome Project.
DNMT1 has a large Nterminal regulatory region and a smaller Cterminal catalytic region ( Fig. 2e) . The highly conserved catalytic region of DNMT1 alone is not sufficient for enzymatic activity, and an allosteric activation through direct interaction of the Nterminal reg ulatory and Cterminal catalytic regions is required for its enzymatic function 15 . The regulatory region contains many proteinprotein interaction domains including PCNAbinding, targetingsequence, zincfinger and bromoadjacent homology domains. The identified mutations occurred in the targetingsequence domain. The targeting sequence domain regulates DNMT1 binding to chromatin during the late S phase and is responsible for persistent association during the G2 and M phases. The proper folding of the targetingsequence domain is crucial for DNMT1 function 16 . To probe the effect of the two muta tions on the targetingsequence domain folding in vitro, we expressed the wildtype targetingsequence domain (amino acids 351-600) and the corresponding p.Tyr495Cys and p.Asp490Glu-Pro491Tyr targetingsequence domain mutants in Escherichia coli. Although the three proteins are well produced in E. coli, only the wildtype targeting sequence is soluble ( Supplementary Fig. 2) . In contrast, the targeting sequence mutants form inclusion bodies, which is a strong indication that they are misfolded ( Supplementary Fig. 2) . Misfolding in the p.Tyr495Cys mutant is not surprising considering that Tyr495 is part of the protein hydrophobic core with an accessible solvent surface area (ASA) of only 0.55 Å 2 in the crystal structure of the wildtype target ing sequence. Asp490 is solvent accessible (ASA = 75.3 Å 2 ) and is therefore unlikely to contribute to the disease phenotype (Fig. 2f) . In agreement with this, Asp490 is not a conserved residue and is replaced by a glutamate in other species (Fig. 2f) . On the other hand, Pro491 has limited solvent accessibility, with an ASA of 25.7 Å 2 and, together with Asp490, is part of the linker region between the βsheet-based and αhelical subdomains of the targeting sequence, suggesting that the constrained conformation of the transproline residue is needed for proper folding.
The targetingsequence domain has been expressed independ ently and has been shown to be an important factor for the structure, function and localization of DNMT1 (refs. [16] [17] [18] [19] . Partial deletion of the targetingsequence domain abolishes enzymatic activity of DNMT1 (ref. 16 ). To investigate the functional implication of the mutant targetingsequence domain, we transfected GFPtagged con structs encompassing the wildtype targeting sequence (amino acids 306-620) and the two targetingsequence mutants (p.Tyr495Cys and p.Asp490Glu-Pro491Tyr) into HeLa cells. Whereas the wildtype targetingsequence domain entered the nucleus and bound to the replication foci during the S phase and to heterochromatin during the G2 phase, the two targetingsequence mutants localized to the cytoplasm and were not able to enter the nucleus ( Fig. 3a-c) . One of the multiple nuclear localization signals of DNMT1 is just upstream of the targetingsequence domain (323KRRK326) 19 , and the mutations likely disrupt the proper folding of DNMT1, preventing the mutant proteins from entering the nuclei. The alterations p.Tyr495Cys and p.Asp490Glu-Pro491Tyr also affect the stability and the enzymatic activity of fulllength DNMT1. We transfected GFPtagged fulllength wildtype and mutant DNMT1 into HeLa cells and treated the cells with cycloheximide for various time lengths. A protein blot analysis showed that the mutant proteins were quickly degraded compared to wildtype DNMT1 (Supplementary Fig. 3 ). The enzymatic activity assay showed that p.Tyr495Cys DNMT1 and p.Asp490Glu-Pro491Tyr DNMT1 have markedly decreased activity compared to wildtype DNMT1 ( Supplementary Fig. 4 and Supplementary Note). These findings show the deleterious effects of these mutations in the targetingsequence domain on the structure, methyltransferase activity and stability of DNMT1.
DNMT1 is one of the components of the DNA replication machin ery during the S phase of the cell cycle 17 . Studies have shown that maintenance of methylation could last past the replication stage, with DNMT1 continuously loaded on heterochromatin after the S phase. The targetingsequence domain was identified as being responsible for this persistent association 20 . Partial deletion of the targeting sequence domain has been shown to abolish the DNMT1 association with heterochromatin after the S phase 20 . To evaluate the hetero chromatin binding of mutant DNMT1, we cotransfected GFPtagged wildtype and p.Tyr495Cys There was also severe neuronal loss and gliosis of the inferior olivary nucleus as well as generalized cerebral atrophy, with a brain weight of 1,085 grams (normal brain weight is 1,300-1,400 grams) without distinct histopathologic alterations or inclusions, which was determined by Bielschowsky silver and immunohistochemical stains for detection of β-amyloid, τ, TDP-43 and α-synuclein. l e t t e r s DNMT1, as well as RFPtagged proliferating cell nuclear antigen (PCNA) as a cell cycle marker, into HeLa cells. Our results show that the mutant DNMT1 only showed normal localization at replication foci during the S phase, as previously described 20 , but did not show binding of heterochromatin during the G2 phase, in contrast to wild type DNMT1 ( Fig. 4a-c Previous studies showed that the replication machinery loading of DNMT1 is not required for genome methylation maintenance 21 , suggesting that DNMT1 binding to heterochromatin after the S phase could be involved in the prolonged methylation maintenance, recruitment of histone deacetylases and chromatin stability preservation in the transcriptionally repressed genome region 20 . The impaired hetero chromatin binding after the S phase likely impairs these important cellular functions. Next, we examined the effect of mutant DNMT1 on the global methylation level using liquid chromatographyelectrospray ioni zation tandem mass spectrometry (LCESIMS/MS) to measure 5methyl2′deoxycytidine (5mdC) levels following enzymatic hydrolysis of genomic DNA 22 . We quantified a total of 24 samples, including 12 affected and 12 genetically related and unaffected sam ples from kindred 1. Our results showed an 8% reduction in 5mdC content in the affected group compared to the unaffected group (P < 0.001) (Supplementary Fig. 5 ). This is predicted to be meaning ful, considering that in DNMT1 knockout HCT116 cells, we observed only 10-20% of genomic DNA hypomethylation but that the deleteri ous impact led to pronounced chromosomal defects and apoptosis 23, 24 . Because methylation varies with age and sex, we specifically compared the content of 5mdC between three pairs of samesex siblings and between two pairs of samesex cousins of similar age (<5 years dif ference in age). The results showed consistent 7-15% reduction of 5mdC content in all affected sibling and cousins (Supplementary Table 2 ). Centromeric and pericentromeric regions have been shown to contribute to the majority of global methylation. We used a pyro sequencing assay of bisulfitetreated DNA to investigate the CpG sites in the repetitive elements of satellite 2, line 1, satellite α and the Alu region. The results suggested reduced methylation at certain CpG sites in the satellite 2 region in the affected group ( Supplementary Table 3 and Supplementary Note). The satellite 2 methylation reduction was further confirmed by DNA blot using genomic DNA digested by methylationsensitive enzyme BstB1 (Supplementary Fig. 6a,b) . These results support global hypomethylation shown by reduced 5mdC content, suggesting the hypomethylation likely occurs at the satellite 2 repetitive elements. The hypomethylation in repetitive and transposable elements has been linked to the loss of methylspecific protein complexes that stabilize a high order of heterochromatin structure 25 . The reduction of total 5mdC content and decreased Figure 3 Localization of the wild-type and mutant targeting sequence domain of DNMT1. We performed confocal microscopy using HeLa cells cotransfected with plasmids containing the RFP-PCNA and GFP-DNMT1 wild-type targeting sequence domain (a), the p.Tyr495Cys targeting sequence domain (b) or the p.Asp490Glu-Pro491Tyr targeting sequence domain (c). Wild-type and mutant targeting sequence domains are shown in green in the left panels, PCNA appears red in the middle panels and the merged images are shown in the right panels. Scale bars, 5 µm. In a, the wild-type targeting sequence domain enters the nucleus during the S phase when PCNA localizes to the toroidal structures of replication foci; the wild-type targeting sequence also binds to heterochromatin during the G2 phase, when PCNA showed a diffused pattern and toroidal structures were no longer visible. (b,c) Mutant targeting sequence domains were unable to enter the nucleus and remained in the cytoplasm. l e t t e r s methylation in satellite 2 resulting from DNMT1 mutations may impair the heterochromatin stability. Because variation in methylation is usually linked to the tran scriptional regulation of specific genes, we investigated the methyla tion of CpG sites in gene promoter regions. We used the Illumina HumanMethylation27 BeadChip to survey genomewide promoter methylation profiles. We studied the 24 samples from kindred 1. Based on the moving average of the methylation difference between the affected and unaffected groups, we observed moderate reduc tion of methylation in the affected samples ( Fig. 5) . Notably, the ten promoter CpG sites with the most significant P values (P < 0.00007) showed increased methylation ( Fig. 5 and Supplementary Fig. 7) . Global hypomethylation of cytosines and local hypermethylation of CpG islands are characteristics of the neoplastic epigenome 26 , but the investigated kindreds did not have any cancer history. One of the characteristics of tumor cells is uncontrolled proliferation. In post mitotic neurons, DNA methylation undergoes a turnover process in response to synaptic activity 27 , and failure of mitotic arrest may result in cell death 4 . Reexpression of various cell cycle proteins has been reported in individuals with Alzheimer's dementia and other neuro degenerative disorders 4 , suggesting that initiation of the cell cycle by abnormal expression of cell cycle proteins impairs neuronal health. It is intriguing to see that the methylation pattern in the affected persons mimics the methylation pattern of tumor cells, leading us to speculate that mutated DNMT1 could be linked to the loss of cell cycle arrest in the postmitotic neuron. Defects of methylation have been shown to cause developmental and progressive human neurodegenerative diseases such as Rett (MeCP2) 28 and immunodeficiency, centromere instability and facial anomalies (DNMT3b) 29 syndromes. Epigenetic dysregulation has also been suggested in Alzheimer's dementia through reduced histone acetylation 30 . Because our chromosoma lly linked region at 19p13.2 also associates with lateonset familial Alzheimer's 31 , possible association of DNMT1 in this disease needs further investigation.
In this report, we identified mutations in DNMT1 that cause HSAN1 with dementia and hearing loss. These mutations affect the proper folding of DNMT1, decrease enzymatic activity, impair hetero chromatin binding ability after the S phase and lead to the occurrence of global hypomethylation with local hypermethylation. Our results provide a direct link between DNMT1 alteration and a neurodegen erative disorder of both the central and peripheral nervous systems. DNMT1 is highly expressed in postmitotic neurons and the adult central nervous system 32 , interacts with a series of important cell cycle regulating proteins 33 and is involved in neuronal differentia tion, migration and central neural connection 1, 34, 35 , suggesting that DNMT1 participates in a precise mechanism of dynamic regulation of the nervous system. The affected individuals in our kindreds had apparent normal intelligence and nerve function until early adult hood, then the typical symptoms began and worsened with age, implicating that the influence of DNMT1 is beyond embryogenesis and suggesting a progressive course with gradual accumulating effect. Our study emphasizes that even moderate global hypomethylation in association with local hypermethylation can have a severe effect on neuronal survival and function. The pathogenic mechanism of mutant DNMT1 is potentially complex and provides a new direction for the study of neurodegeneration.
RFP-PCNA Merge Figure 4 Heterochromatin and replication foci binding of wild-type and mutant DNMT1. We performed confocal microscopy using HeLa cells cotransfected with plasmids containing RFP PCNA and full-length GFP wild-type DNMT1 (a), GFP p.Tyr495Cys DNMT1 (b) or GFP p.Asp490Glu-Pro491Tyr DNMT1 (c). Wild-type and mutant DNMT1 appear in green in the left panels, PCNA appears in red in the middle panels and merged images are shown in the right panels. Scale bars, 5 µm. We deciphered cell cycles from the pattern of RFP-PCNA. In the S phase, PCNA is present at the toroidal structures of the replication foci; in the G2 phase, PCNA shows a diffused pattern in the nucleus. In a, wild-type DNMT1 co-localizes with PCNA at replication foci during the S phase and binds to heterochromatin during the G2 phase. In b and c, p.Tyr495Cys DNMT1 and p.Asp490Glu-Pro491Tyr DNMT1 localize with PCNA at the replication foci during the S phase but did not show binding of heterochromatin during G2 phase. Figure 5 Methylation profile difference between the affected and the unaffected groups. A moving average of methylation difference of ~25,000 CpG sites between the affected and unaffected groups from kindred 1. We chose kindred 1 to optimize the same number of gender and the firstdegree relations between the affected and unaffected groups. We compared the methylation profile of affected and unaffected groups. The y axis represents the methylation difference between the two groups. The x axis represents P values. The red colored line represents the moving average of methylation difference between the affected and unaffected group. Each blue dot represents the methylation difference for a CpG site. Blue dots below the 0 line represent reduced methylation in the affected group, and blue dots above the 0 line represent increased methylation in the affected group. The red moving average line suggests local hypermethylation and moderate global hypomethylation in the affected group, consistent with the 5-mdC content measurement by LC-ESI-MS/MS (supplementary Fig. 5 ).
URLs. Human Genome Mutation Database (HGMD), http:// www.hgmd.cf.ac.uk/; The 1000 Genome Browser, http:// browser.1000genomes.org/index.html; Environmental Genome Project, http://www.niehs.nih.gov/research/supported/programs/ egp/; PyMOL, http://www.pymol.org/; MAQ, http://maq.sourceforge. net/; BWA, http://biobwa.sourceforge.net/bwa.shtml.
METHODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. Protein Data Bank accession number for DNMT1 targeting sequence domain, 3EPZ; accession code for DTMN1, NM_ 001379; exome sequencing data is available upon request through the FTP site.
Note: Supplementary information is available on the Nature Genetics website.
Illumina Infinium HumanMethylation27 BeadChip analysis. One micro gram DNA from each selected sample was bisulfite treated using the Zymo Methylation kit (Zymo Research). After bisulfite conversion, 250 ng of each sample underwent a wholegenome amplification followed by hybridization. Allelespecific primer annealing was followed by singlebase extension with labeled nucleotides. After extension, the array was scanned, and the intensities of the unmethylated and methylated bead types were measured. The meth ylation level at each CpG site was determined by measuring the methylation fraction (β), defined as the fraction of methylated signal over the total signal (unmethylated + methylated). The β values are continuous variables between 0 (unmethylated) and 1 (completely methylated). The Infinium Assay includes redundant, builtin, bisulfite conversion quality controls that measure the con version rate of nonCpG cytosines and background signal. Using withinassay controls evaluated with Illumina GenomeStudio software, we assessed back ground signal and bisulfite conversion rate and ensured that nonmethylated cytosines in all 24 samples were efficiently bisulfite converted. Approximately 8% of CpG sites that did not reveal reliable signals, as determined by their detection P value, were excluded from further analysis. Differential meth ylation analysis and construction of a volcano plot was performed using the Partek Statistical Package (Partek). We employed twoway analysis of variance to account for the potential batch effects. The type I error was controlled by the use of Benjamini and Hochberg false discovery rate controlling procedure.
